Vaxcyte Inc (NASDAQ: PCVX) on Friday, soared 0.38% from the previous trading day, before settling in for the closing price of $93.98. Within the past 52 weeks, PCVX’s price has moved between $48.81 and $121.06.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 5.15%. With a float of $119.89 million, this company’s outstanding shares have now reached $124.64 million.
Let’s look at the performance matrix of the company that is accounted for 254 employees. In terms of profitability, gross margin is 2.95%, operating margin of -3662.28%, and the pretax margin is -3514.11%.
Vaxcyte Inc (PCVX) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Vaxcyte Inc is 3.81%, while institutional ownership is 107.25%. The most recent insider transaction that took place on Nov 18 ’24, was worth 686,518. In this transaction PRESIDENT AND CFO of this company sold 8,000 shares at a rate of $85.81, taking the stock ownership to the 109,491 shares. Before that another transaction happened on Nov 18 ’24, when Company’s Officer proposed sale 8,000 for $86.50, making the entire transaction worth $692,000.
Vaxcyte Inc (PCVX) Latest Financial update
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -1.82 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.99) by -0.83. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 5.15% per share during the next fiscal year.
Vaxcyte Inc (NASDAQ: PCVX) Trading Performance Indicators
Vaxcyte Inc (PCVX) is currently performing well based on its current performance indicators. A quick ratio of 17.88 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.68, a number that is poised to hit -1.12 in the next quarter and is forecasted to reach -4.69 in one year’s time.
Technical Analysis of Vaxcyte Inc (PCVX)
Vaxcyte Inc (NASDAQ: PCVX) saw its 5-day average volume 1.17 million, a positive change from its year-to-date volume of 0.91 million. As of the previous 9 days, the stock’s Stochastic %D was 99.39%. Additionally, its Average True Range was 4.22.
During the past 100 days, Vaxcyte Inc’s (PCVX) raw stochastic average was set at 47.21%, which indicates a significant increase from 43.26% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 44.76% in the past 14 days, which was lower than the 60.57% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $106.03, while its 200-day Moving Average is $83.57. Nevertheless, the first resistance level for the watch stands at $95.15 in the near term. At $95.97, the stock is likely to face the second major resistance level. The third major resistance level sits at $97.57. If the price goes on to break the first support level at $92.74, it is likely to go to the next support level at $91.15. The third support level lies at $90.33 if the price breaches the second support level.
Vaxcyte Inc (NASDAQ: PCVX) Key Stats
Market capitalization of the company is 11.80 billion based on 124,637K outstanding shares. Right now, sales total 0 K and income totals -402,270 K. The company made 0 K in profit during its latest quarter, and -103,120 K in sales during its previous quarter.
